Dialysis facility and network factors associated with low kidney transplantation rates among United States dialysis facilities.

Variability in transplant rates between different dialysis units has been noted, yet little is known about facility-level factors associated with low standardized transplant ratios (STRs) across the United States End-stage Renal Disease (ESRD) Network regions. We analyzed Centers for Medicare & Medicaid Services Dialysis Facility Report data from 2007 to 2010 to examine facility-level factors associated with low STRs using multivariable mixed models. Among 4098 dialysis facilities treating 305 698 patients, there was wide variability in facility-level STRs across the 18 ESRD Networks. Four-year average STRs ranged from 0.69 (95% confidence interval [CI]: 0.64-0.73) in Network 6 (Southeastern Kidney Council) to 1.61 (95% CI: 1.47-1.76) in Network 1 (New England). Factors significantly associated with a lower STR (p < 0.0001) included for-profit status, facilities with higher percentage black patients, patients with no health insurance and patients with diabetes. A greater number of facility staff, more transplant centers per 10 000 ESRD patients and a higher percentage of patients who were employed or utilized peritoneal dialysis were associated with higher STRs. The lowest performing dialysis facilities were in the Southeastern United States. Understanding the modifiable facility-level factors associated with low transplant rates may inform interventions to improve access to transplantation.

Family history of end-stage renal disease does not predict dialytic survival.

Familial aggregation of end-stage renal disease (ESRD) is frequently observed in the common causes of kidney failure. It is unknown whether the clinical course of nephropathy differs based on an individual's family history of ESRD. The ESRD Network 6 Family History of ESRD database was analyzed to compare dialytic survival among patients with first- or second-degree relatives on dialysis therapy (positive family history) with those lacking relatives with ESRD (negative family history). Study participants included 3,442 adult, black or white, incident patients with ESRD who initiated dialysis therapy in ESRD Network 6 facilities in 1995 and participated in the Network-sponsored Family History of ESRD study. All deaths were reported to the Network and used to calculate mortality rates. The relative risk for death was used to compare rates between levels of patient characteristics. Multivariate analyses used proportional hazards regression. Overall, 730 patients (21.2%) had a positive family history of ESRD. Black patients, those who were younger at the onset of ESRD, patients with greater degrees of functional status, and women were more likely to have a positive family history. During 9,000 patient-years of follow-up, 1,599 patients died (17.8 deaths/100 dialysis-years). Univariate analyses showed that patients with a positive family history of ESRD had 20% lower mortality than those with a negative family history of ESRD (relative risk, 0.80; 95% confidence interval, 0.7 to 0.9; P = 0.001). Older age, white race, diabetic nephropathy, lower functional status, lower serum albumin level, congestive heart failure, and ischemic heart disease also were associated with greater mortality rates. Multivariate analyses showed that only older age at onset of ESRD, white race, low functional status, ESRD caused by diabetes, and congestive heart failure were associated with increased mortality. A family history of ESRD in either first- or second-degree relatives was no longer a significant determinant of survival. We conclude that familial clustering of ESRD does not significantly impact on dialytic survival after controlling for the competing effects of patient race, age of ESRD onset, and the presence of diabetes mellitus.

Promoting quality of care for ESRD patients: the role of the ESRD Networks.

The 18 End Stage Renal Disease (ESRD) Networks were established by Congress to oversee the care of Medicare beneficiaries with ESRD, serving as HCFA's primary quality improvement (QI) agents. The Networks play a critical role in the ESRD surveillance system by collecting, analyzing and disseminating data from dialysis clinics regarding the occurrence of ESRD, and the processes of care and outcomes of ESRD patients. In addition, under the direction of volunteer Medical Review Boards, the Networks propose, design and implement regional QI activities targeting specific areas in the delivery of ESRD care, and provide technical assistance to foster QI at the facility level. In this article, we discuss the ESRD Network system and review the scope of QI activities through which the Networks accomplish their mission.

Racial variation in autosomal dominant polycystic kidney disease.

These analyses were undertaken to determine whether racial variation contributes to the risk of end-stage renal disease (ESRD) in close relatives of incident dialysis patients with autosomal dominant polycystic kidney disease (ADPKD)-associated ESRD. A family history of ESRD was recorded in 14,769 incident ESRD patients in Network 6 (Georgia, North Carolina, South Carolina) between September 1993 and November 1997. Two hundred thirty-seven patients with ADPKD-ESRD comprised the study population (180 white and 57 black). Differences in patient populations were analyzed using the chi-squared and Student's t-tests, and multiple regression analysis was performed. Correlation in age at ESRD onset in families was performed by linear regression analysis. A positive family history (FH) of ESRD in first- or second-degree relatives was reported by 38.6% (22 of 57) of blacks and 55% (99 of 180) of whites (P = 0.03). The 22 blacks with a positive FH had a mean of 2.0 additional ESRD relatives and 10.4 total first-degree relatives, whereas the 99 whites with a positive FH had a mean of 2.6 additional ESRD relatives and 7.0 total first-degree relatives (P = 0.14 and P < 0.001, respectively). Mean age in years at first dialysis was similar in blacks and whites, regardless of FH (black FH positive, 63.8; black FH negative, 66.3; P = 0.66; white FH positive, 60.8; white FH negative, 62.8; P = 0. 48). On average, 57.9% of the first- and second-degree relatives of white cases had ADPKD-associated ESRD, compared with 28.6% of the relatives of black cases (P < 0.001). In the multivariate analysis, white race (P = 0.004) and increasing family size (P = 0.002) were positively correlated with the number of relatives having ADPKD-associated ESRD, whereas age at ESRD onset (P = 0.50) and gender (P = 0.94) were not. Age at onset of ESRD was correlated within members of multiply affected white (P < 0.001) but not black families (P = 0.80). We conclude that blacks with ADPKD-associated ESRD are less likely than whites to have relatives with ESRD, and there is no correlation in age at onset of ADPKD-ESRD in black families.

Improving the care of patients treated with hemodialysis: a report from the Health Care Financing Administration's ESRD Core Indicators Project.

To determine the impact of a quality improvement intervention on dialysis care delivered to hemodialysis patients, we studied 213 hemodialysis facilities in North Carolina, South Carolina, and Georgia. Dialysis adequacy measurements made on two random samples of 30 patients per treatment center, or all patients if fewer than 30 were treated, selected in October 1994 (preintervention) and October 1995 (postintervention) were used to estimate the facility mean urea reduction ratio (URR) and the proportion of patients with a mean URR less than 50%. The 10% of facilities (n = 22) with the highest proportion of patients with a mean URR less than 50% in the facility at preintervention were selected for an intervention that included feedback of facility-specific mean URR, educational programs, a quality improvement workshop, and monitoring until improvement was attained. Changes between preintervention and postintervention facility mean URR and proportions of patients with a URR less than 60% and 65% were used to assess the impact of the intervention. After 1 year, the mean URR had increased an average of 7% in intervention centers compared with an increase of 1.4% (P < 0.001) in the remainder of the treatment centers in the Network. There was an average reduction of 17.2% in the proportion of patients with a URR less than 65% in intervention centers compared with 4.8% in the other facilities (P < 0.001). Comparable reductions in the proportion of patients with a mean URR of less than 60% were 16.2% in intervention centers and 2.0% in comparison facilities (P < 0.001). After controlling for facility case mix and other characteristics, the intervention was independently associated with an absolute 2.4% increase in facility-specific mean URR. We conclude that the intervention was associated with improvement in hemodialysis care.

Ethnic differences in the use of peritoneal dialysis as initial treatment for end-stage renal disease.

OBJECTIVE: To evaluate the influence of ethnicity on the use of peritoneal dialysis (PD) as initial treatment for end-stage renal disease (ESRD) after controlling for other patient characteristics. DESIGN: Inception cohort analysis of incident ESRD patients. PATIENTS: All African-American and white patients (N = 10,726) who began treatment for ESRD at dialysis centers in North Carolina, South Carolina, and Georgia and reported to ESRD Network 6 between January 1, 1989, and December 31, 1991. MAIN OUTCOME MEASURE: Odds ratios (ORs) of the association between ethnicity and PD as initial treatment modality. RESULTS: African-American patients were 56% less likely than whites to use PD (OR, 0.44; 95% confidence interval [CI], 0.40 to 0.49). This difference persisted (OR, 0.45; 95% CI, 0.38 to 0.52) after multivariable adjustment for age, education, social support, home ownership, functional status, albumin level, hypertension, history of myocardial infarction, peripheral neuropathy, and comorbid diabetes. CONCLUSIONS: Ethnic differences in initial PD use cannot be explained by many demographic, socioeconomic, and comorbid factors associated with the use of PD as initial treatment for ESRD.